Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

34.38
+0.88002.63%
Volume:4.67M
Turnover:160.75M
Market Cap:3.86B
PE:-22.34
High:35.22
Open:33.83
Low:33.53
Close:33.50
Loading ...

Earnings Flash (VKTX) Viking Therapeutics Q1 Loss of $0.41 vs. FactSet Est Loss $0.33

MT Newswires Live
·
24 Apr

Viking Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
24 Apr

Viking Therapeutics reports Q1 EPS (41c), consensus (31c)

TIPRANKS
·
24 Apr

Viking Therapeutics Q1 GAAP EPS $(0.41) Misses $(0.34) Estimate

Benzinga
·
24 Apr

Viking Therapeutics options imply 8.5% move in share price post-earnings

TIPRANKS
·
24 Apr

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Zacks
·
21 Apr

Viking Therapeutics to Report Q1 Earnings: What's in the Cards?

Zacks
·
21 Apr

Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic's Competition Grows -- Barrons.com

Dow Jones
·
19 Apr

H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data

TipRanks
·
18 Apr

JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics

TipRanks
·
18 Apr

Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know

Zacks
·
18 Apr

Viking Therapeutics Price Target Maintained With a $102.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Apr

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Motley Fool
·
18 Apr

Lilly's Weight-Loss Pill Shocks Wall Street

GuruFocus.com
·
17 Apr

BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial

Reuters
·
17 Apr

Eli Lilly's stock soars as successful trial of weight-loss pill is a game changer

Dow Jones
·
17 Apr

Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

PR Newswire
·
17 Apr

Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?

Zacks
·
16 Apr

Viking Therapeutics’ VK2735: A Promising Contender Amidst Pfizer’s Setback

TIPRANKS
·
16 Apr

Promising Pipeline and Strategic Developments Drive Buy Rating for Viking Therapeutics

TIPRANKS
·
16 Apr